| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 10 May 2023 | Announcement of General Shareholders’ Meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
| 21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
| 21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 29 Apr 2014 | Información sobre resultados | Download | |
| 29 Apr 2014 | Convocatorias y Acuerdos de Juntas y Asambleas Generales | Download | |
| 27 Feb 2014 | Información sobre resultados (2) | Download | |
| 27 Feb 2014 | Información sobre resultados | Download | |
| 27 Feb 2014 | Informe anual de gobierno corporativo 2013 | Download |